The abstract is read at the publisher; the summary is JClub's.
Partitioned polygenic risk scores in UK Biobank identify a MASLD subtype with a glucose-lowering axis, linked to GCKR rs1260326, that lowers fasting glucose and type 2 diabetes risk.
- Why it matters: MASLD can coexist with improved glycaemic outcomes, but the genetic basis for this favourable subtype and how steatosis aligns with lower diabetes risk is unclear.
- What they did: The study integrated genetics with triglyceride-related metabolomics to cluster 18 MASLD-associated variants and built mutually adjusted partitioned PRSs, then tested hepatic biomarkers, liver outcomes, and type 2 diabetes, replicating glycaemic effects in TZL.
- The result: Colocalisation and fine-mapping prioritized GCKR rs1260326 (C>T) as a shared MASLD–type 2 diabetes signal; allele-specific assays showed the T allele promotes exon-15 skipping, reduces full-length GKRP abundance, and produces a truncated protein.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.